Pediatrix Medical GroupFRA:PDC -0.94%57 Altman Z-Score is 2.43 as of Jun. 27, 2026, which is 47% above its 10-year median of 1.65. GuruFocus rates FRA:PDC with a GF Score™ of 57/100 and a GF Value™ of €11.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 50.45% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.42 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Pediatrix Medical Group has a Altman Z-Score of 2.43, indicating it is in Grey Zones. This implies that Pediatrix Medical Group is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Pediatrix Medical Group's Altman Z-Score or its related term are showing as below:
FRA:PDC'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.79 Med: 1.65 Max: 3.39
Current: 2.42
During the past 13 years, Pediatrix Medical Group's highest Altman Z-Score was 3.39. The lowest was 0.79. And the median was 1.65.
Pediatrix Medical Group (FRA:PDC) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDC vs SGRY, ADUS, SNDA: Altman Z-Score Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's Altman Z-Score falls into.
Pediatrix Medical Group Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Pediatrix Medical Group (FRA:PDC) has a Altman Z-Score of 2.43 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Pediatrix Medical Group and its competitors. This is 47% above median its historical median of 1.65. Over the past decade, Pediatrix Medical Group's Altman Z-Score has ranged from 0.79 to 3.39. According to the industry distribution chart, Pediatrix Medical Group ranks #328 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 49.5%.
Is Pediatrix Medical Group's Altman Z-Score too high?
Pediatrix Medical Group's current Altman Z-Score of 2.43 is 47% above median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 3.39. The Healthcare Providers & Services industry median Altman Z-Score is 2.36. Pediatrix Medical Group's value of 2.43 is 3% above this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #328 out of 662 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Altman Z-Score compare to SGRY and ADUS?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #328 out of 662 companies for Altman Z-Score. This puts Pediatrix Medical Group in the upper half of its industry. The industry median Altman Z-Score is 2.36. Pediatrix Medical Group's value of 2.43 is 3% above this benchmark. Historically, Pediatrix Medical Group's own Altman Z-Score has ranged from 0.79 to 3.39 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 2.36, Pediatrix Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.36, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current Altman Z-Score of 2.43 is 3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Pediatrix Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current Altman Z-Score is 2.43, which is 47% above median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.17, compared to a current price of €21.00 — trading 88% above its estimated fair value. The current Altman Z-Score is 2.43, which is 47% above median its 10-year median of 1.65 and 3% above the Healthcare Providers & Services industry median of 2.36. Pediatrix Medical Group's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Altman Z-Score is 2.43 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €21.00 is trading 88% above its estimated GF Value™ of €11.17.
GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.
Key valuation signals for FRA:PDC:
Altman Z-Score: 2.43 (47% above median its 10-year median of 1.65)
GF Value™: €11.17 vs. price of €21.00 (88% above fair value)
Industry Position: 3% above the Healthcare Providers & Services median (#328 of 662)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
57GF Score
Get the complete analysis for FRA:PDC
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
